Search results for "Type"

showing 10 items of 10618 documents

Impact of chronic diuretic treatment on glucose homeostasis

2013

Background The use of diuretics for hypertension has been associated with unfavorable changes in cardiovascular risk factors, such as uric acid and glucose tolerance, though the findings in the literature are contradictory. Methods This study investigated whether diuretic use is associated with markers of metabolic and cardiovascular risk, such as insulin-resistance and uric acid, in a cohort of adults without known diabetes and/or atherosclerotic cardiovascular disease. Nine hundred sixty-nine randomly selected participants answered a questionnaire on clinical history and dietary habits. Laboratory blood measurements were obtained in 507 participants. Results Previously undiagnosed type 2 …

medicine.medical_specialtySettore MED/09 - Medicina InternaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentSettore MED/50 - Scienze Tecniche Mediche ApplicateType 2 diabetesGastroenterologySettore MED/13 - Endocrinologiachemistry.chemical_compoundInsulin resistanceDiabetes mellitusInternal medicineInternal MedicinemedicineGlucose homeostasisSettore MED/49 - Scienze Tecniche Dietetiche ApplicateDiureticsbusiness.industryResearchInsulin resistanceType 2 diabetesmedicine.diseaseDiuretics Hypertension Insulin resistance Type 2 diabetes Uric acidEndocrinologychemistryHypertensionCohortUric acidDiureticbusinessUric acidBody mass index
researchProduct

Inverse association between type 2 diabetes and aortic root dimension in hypertensive patients

2017

Background Some data support the concept that aortic root diameter (ARD) in hypertension may be regarded as a marker of subclinical organ damage. The impact of type 2 diabetes mellitus (DM) on cardiac structure and function is known, although the relationship between DM and ARD is not clear. The aim of our study was to evaluate the influence of DM on ARD in hypertensive patients. Methods We enrolled 1693 hypertensive patients (aged 63.7 ± 9.6 years). The population was divided into two groups: the first one with DM (n = 747) and the second one without DM (n = 946). ARD was measured by echocardiography at level of Valsalva's sinuses using echocardiography M-mode tracings. It was considered a…

medicine.medical_specialtySettore MED/09 - Medicina InternaPopulationType 2 diabetes030204 cardiovascular system & hematologyDoppler imagingType 2 diabeteSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineBayesian multivariate linear regressionInternal medicinemedicine030212 general & internal medicineeducationSubclinical infectionBody surface areaeducation.field_of_studybusiness.industryConfoundingType 2 Diabetes Mellitusmedicine.diseaseCardiovascular riskSettore MED/11 - Malattie Dell'Apparato CardiovascolareEndocrinologyEchocardiographyHypertensionCardiologyCardiology and Cardiovascular MedicinebusinessAortic root diameter
researchProduct

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retr…

2021

Abstract Background Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis (LA). Lomitapide is an emerging therapy in HoFH, but its place in the treatment algorithm is disputed because a comparison of its long-term efficacy versus LA in reducing LDL-C burden is not available. We assessed changes in long-term LDL-C burden and goals achievement in two independent HoFH patients’ cohorts, one treated with lomitapide in Ita…

medicine.medical_specialtySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]LipoproteinsGenetic diseaseTherapeuticsFamilial hypercholesterolemiaDiseaseLipoprotein apheresiLDLHyperlipoproteinemia Type IIchemistry.chemical_compoundLipoprotein apheresisRetrospective surveyInternal medicineCholesterol burden; Genetic disease; Homozygous hypercholesterolemia; LDL; Lipoprotein apheresis; Lomitapide; Therapeutics; Benzimidazoles; Homozygote; Humans; Lipoproteins; Retrospective Studies; Anticholesteremic Agents; Blood Component Removal; Hyperlipoproteinemia Type IImedicineHumansPharmacology (medical)Genetics (clinical)Retrospective Studiesmedicine.diagnostic_testbusiness.industryResearchAnticholesteremic AgentsHomozygous hypercholesterolemiaHomozygoteRGeneral Medicinemedicine.diseaseLomitapideLomitapidecholesterol burden; genetic disease; homozygous hypercholesterolemia; LDL; lipoprotein apheresis; lomitapide; therapeuticsCholesterol burdenchemistryCohortBlood Component RemovalMedicineTherapeutics.BenzimidazolesLipid profilebusinessLipoprotein apheresisCross nationalOrphanet Journal of Rare Diseases
researchProduct

Simultaneous endovascular treatment of synchronous symptomatic acute type B aortic dissection and large infrarenal aortic aneurysm. Technical tips an…

2020

Highlights • Acute type B aortic dissection associated with AAA, has a high rupture risk. • This complicated dissection must be considered for treatment as quickly. • This approach can be performed endovascularly when supraaortic trunks are involved. • Totally endovascular solution to address both disease is feasible.

medicine.medical_specialtySettore MED/22 - Chirurgia Vascolare03 medical and health sciencesAortic aneurysm0302 clinical medicinemedicine.arteryCase reportmedicineRupture riskSuperior mesenteric arterycardiovascular diseasesEndovascular treatmentAortic dissectionbusiness.industryPETTICOATmedicine.diseaseAbdominal aortic aneurysmSurgeryAcute type030220 oncology & carcinogenesiscardiovascular system030211 gastroenterology & hepatologySurgeryComplicated aortic B dissectionbusinessComplicationInternational Journal of Surgery Case Reports
researchProduct

Uncoupling Protein 2 as genetic risk factor for systemic lupus erythematosus: association with malondialdehyde levels and intima media thickness

2020

BACKGROUND Increased oxidative stress potentially leads to accelerated atherosclerosis and, consequently, cardiovascular diseases, the main cause of death in systemic lupus erythematous (SLE). To gain insight into these mechanisms, we studied the association of uncoupling protein (UCP) 2 genetic variants, gene involved in the mitochondrial production of reactive oxygen species, and oxidative stress with SLE and the presence of atherosclerosis. METHODS Genetic analysis of the UCP2 -866G/A and UCP2 Ins/Del polymorphisms was performed in 45 SLE patients and 36 healthy controls by RFLP-PCR. Oxidation status was determined by measuring malondialdehyde (MDA) levels. Presence of subclinical athero…

medicine.medical_specialtySingle-nucleotide polymorphism030204 cardiovascular system & hematologymedicine.disease_causeCarotid Intima-Media Thickness03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGeneticRisk FactorsMalondialdehydeInternal medicineGenotypemedicineHumansUncoupling proteinUncoupling Protein 2030212 general & internal medicineAlleleskin and connective tissue diseaseschemistry.chemical_classificationReactive oxygen speciesbusiness.industryMalondialdehydeLupus erythematosus systemicEndocrinologychemistryIntima-media thicknessCardiology and Cardiovascular MedicinebusinessCardiovascular diseases.Oxidative stressMinerva Cardioangiologica
researchProduct

Cerebriform sebaceous nevus: a subtype of organoid nevus due to specific postzygotic FGFR2 mutations.

2021

Background Postzygotic mutations in FGFR2 have been identified in mosaic forms of acne, keratinocytic epidermal nevi, nevoid acanthosis nigricans / rounded and velvety epidermal nevus and in two fetuses with papillomatous pedunculated sebaceous nevus (PPSN). Objectives To determine the clinical and genetic characteristics of children with cerebriform, papillomatous, and pedunculated variants of sebaceous nevi. Methods Infants diagnosed with sebaceous nevi characterized by a cerebriform, papillomatous, and/or pedunculated morphology over a 10-year period (2010 - 2019) at three pediatric dermatology centers in Switzerland and France were included in this case series. Clinical and histological…

medicine.medical_specialtySkin NeoplasmsCutis gyrataDermatologyEpidermal nevusmedicine.disease_causeGermline030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineNevusHumansPediatric dermatologyReceptor Fibroblast Growth Factor Type 2skin and connective tissue diseasesAcanthosis nigricansNevusMutationintegumentary systembusiness.industryOrganoid Nevusmedicine.diseaseDermatologyOrganoidsInfectious Diseases030220 oncology & carcinogenesisMutationbusinessJournal of the European Academy of Dermatology and Venereology : JEADVReferences
researchProduct

Growth and differentiation factor 11 (GDF11): Functions in the regulation of erythropoiesis and cardiac regeneration

2015

International audience; Members of the TGF-β superfamily transduce their signals through type I and II receptor serine/threonine kinases. The binding of activins to activin type IIA (ActRIIA) or type IIB (ActRIIB) receptors induces the recruitment and phosphorylation of an activin type I receptor (ALK4 and/or ALK7), which then phosphorylates the Smad2 and Smad3 intracellular signaling proteins. The regulation of members of the TGF-β family is known to be complex, because many proteins able to bind the ligands and inhibit their activities have been identified. Growth and differentiation factor 11 (Gdf11) belongs to the TGF-β family. GDF11, like other members of the TGF-β superfamily, is prod…

medicine.medical_specialtySmad2 ProteinProtein Serine-Threonine Kinases030204 cardiovascular system & hematologyBiology03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineTGF beta signaling pathway[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineHumansRegeneration[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyPharmacology (medical)PhosphorylationCCL11Activin type 2 receptors030304 developmental biologyPharmacology0303 health sciencesR-SMADcardiac regenerationGrowth differentiation factorHeartActivins[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemCell biologyBMPR2Growth Differentiation FactorsEndocrinologyBone Morphogenetic ProteinsGDF11Smad2 ProteinSignal transductionActivin Receptors Type IerythropoiesisACVR2BSignal TransductionPharmacology & Therapeutics
researchProduct

Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?

2005

The term "lipid triad" or "atherogenic lipoprotein phenotype" has been introduced to describe a common form of dyslipidemia, characterized by three lipid abnormalities: increased plasma triglyceride levels, decreased HDL-cholesterol concentrations and the presence of small, dense LDL particles. It has been suggested that the clinical importance of the atherogenic lipoprotein phenotype probably exceeds that of LDL-cholesterol, because many more patients with coronary artery disease are found to have this trait than hypercholesterolaemia. There is a body of evidence that therapies effective against plasma HDL-cholesterol and triglycerides are associated with a strong reduction of cardiovascul…

medicine.medical_specialtySmall dense ldlBiologyCoronary artery diseaseCardiovascular preventionInternal medicineInternal MedicinemedicineHumansNational Cholesterol Education ProgramDyslipidemiasHypolipidemic AgentsLDL HDL triglycerides preventionBiochemistry (medical)LDL Particle SizeTriad (anatomy)Atherogenic lipoprotein phenotypemedicine.diseaseAtherosclerosisLipoproteins LDLEndocrinologymedicine.anatomical_structureCardiovascular Diseaseslipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineDyslipidemiaJournal of atherosclerosis and thrombosis
researchProduct

Update on the role of the atherogenic lipoprotein phenotype in cardiovascular prevention

2009

Higher plasma triglyceride levels and decreased HDL-cholesterol concentrations are usually accompanied by the presence of small, dense LDL in the so-called lipid triad or ‘atherogenic lipoprotein phenotype’. This phenotype is highly atherogenic and its prevalence may suggest an even higher overall burden of atherosclerotic disease as compared with that associated with hypercholesterolemia. As stated by the National Cholesterol Education Program Adult Treatment Panel III, there is evidence suggesting each component of this lipid triad is individually atherogenic. However, the relative contribution of each component cannot be easily determined. Therefore, it has been suggested to consider th…

medicine.medical_specialtySmall dense ldlbusiness.industryAtherosclerotic diseaseAtherogenic lipoprotein phenotype dense LDL gradient gel electrophoresis HDL-cholesterol triglyceridesAtherogenic lipoprotein phenotypePhenotypeEndocrinologyCardiovascular preventionPlasma triglycerideInternal medicineMolecular MedicineMedicinelipids (amino acids peptides and proteins)Risk factorCardiology and Cardiovascular MedicinebusinessNational Cholesterol Education ProgramFuture Cardiology
researchProduct

Should we measure routinely the LDL peak particle size?

2004

Low density lipoproteins (LDL) do not show in humans a normal distribution and comprise two different main fractions: large, buoyant (phenotype pattern A) and small, dense (phenotype pattern B) particles, that differ not only in size and density but also in physicochemical composition, metabolic behaviour and atherogenicity. The prevalence of small, dense LDL changes with age (30-35% in adult men, 5-10% in men <20 years and in pre-menopausal women, 15-25% in postmenopausal women) and is genetically influenced, with a heritability ranging from 35% to 45%. Small, dense LDL correlate negatively with plasma HDL levels and positively with plasma triglyceride levels and are associated with the me…

medicine.medical_specialtySmall dense LDLAcute myocardial infarctionCoronary artery diseaseRisk FactorsDiabetes mellitusInternal medicineDiabetes MellitusmedicineHumansMyocardial infarctionParticle SizeRisk factorNational Cholesterol Education ProgramTriglyceridesMetabolic Syndromebusiness.industryVascular diseasePreventionmedicine.diseaseLipoproteins LDLCoronary heart diseasePhenotypeCardiovascular DiseasesAtherosclerosiCirculatory systemCardiologylipids (amino acids peptides and proteins)Metabolic syndromeLipoproteins HDLCardiology and Cardiovascular Medicinebusiness
researchProduct